Pacira BioSciences, Inc.

As of June 30, 2026, Pacira Biosciences, Inc. carries a market capitalization of 884.06M, placing it among publicly traded companies globally. Its enterprise value stands at 1.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pacira Biosciences, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Pacira Biosciences, Inc. has 39.82M shares outstanding.

As of June 30, 2026, Pacira Biosciences, Inc. trades at a trailing price-to-earnings ratio of 72.10. The price-to-sales ratio is 1.41, and the price-to-book ratio stands at 1.50.

As of June 30, 2026, Pacira Biosciences, Inc. trades at an EV/EBITDA multiple of 11.15 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 58.93 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Pacira Biosciences, Inc. trades at an EV/FCF ratio of 6.15, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.03B versus a market cap of 884.06M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pacira Biosciences, Inc. maintains a current ratio of 5.04, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 61.33, indicating elevated leverage, while an interest coverage ratio of 7.89 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pacira Biosciences, Inc. posted a return on equity (ROE) of 2.05, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.33 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.05, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.08, useful for judging operating efficiency across full business cycles. The company generates approximately 797,213.73 in revenue per employee across its workforce of 819.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.10 indicates how many times Pacira Biosciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pacira Biosciences, Inc. recorded 2.63M in income tax expense. That works out to an effective tax rate of 17.06, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 15.45M, leaving 12.81M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Pacira Biosciences, Inc.'s stock has gained approximately 75.14% over the past 52 weeks. The 50-day moving average sits at 24.18, while the 200-day moving average is 21.16.

Over the twelve months ended June 30, 2026, Pacira Biosciences, Inc. generated 653.12M in revenue and converted that into 12.81M in net income, yielding earnings per share of 0.30. EBITDA reached 91.93M, while operating income came in at 16.38M.

As of June 30, 2026, Pacira Biosciences, Inc. holds 219.73M in cash and equivalents against 360.73M in total debt, resulting in a net debt position of 137.64M. Total book value stands at 588.18M, with working capital of 431.70M providing operational flexibility.

Pacira Biosciences, Inc. produced 164.26M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7.13M in capital expenditures, free cash flow totaled 157.13M - equivalent to 3.78 per share.

Over the twelve months ended June 30, 2026, Pacira Biosciences, Inc. posted a gross margin of 79.21, reflecting its pricing power and cost economics. The operating margin of 2.51 and net profit margin of 1.96 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 16.79, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 37.25, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Pacira Biosciences, Inc. shareholders.

As of June 30, 2026, Pacira Biosciences, Inc. has an Altman Z-Score of 2.26, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.